Media

News

Breaking News | Virogin’s First Oncolytic Virus VG161 Receives Breakthrough Therapy Designation in China

Virogin Secures Oral Presentation at ESMO 2024 with New Clinical Data on VG201

Virogin Biotech Oncolytic Virus VG161 Benefit in HCC Patients Featured at ASCO 2024 and Case Reports in Sarcoma Published in Oncology Letters

Virogin Announces its Publication of HPV mRNA cancer vaccine expressing APC-targeting antigen in Immunology

Virogin Announces its Publication of Homologous Prime Boost Strategy using HER-2 expressing Oncolytic HSV-1 in Vaccines

Virogin announced its publication of Monkeypox mRNA vaccine on Nature Communications

VIROGIN Receives FDA Fast Track Designation for VG161, a Novel Therapy Candidate for the Treatment of Advanced Hepatocellular Carcinoma

VG161 granted for FDA Orphan Drug Designation

New Research Progress on VG301 Development

Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors

Virogin Biotech Receives IND Approval from the U.S. FDA for VG201

Virogin Biotech Receives IND Approvals from Chinese NMPA for VG201 and VG161

Conferences

Oncolytic Virotherapy Summit

December 6 - 8, 2022

Boston, Massachusetts. Jeff Lange, Virogin Biotech EVP Business Development, will present “New strategies for oncolytic virotherapy: turning anti-viral immunity to anti-tumor” at a session on Novel Combination Therapies to Maximize Anti-Cancer Effectiveness on December 6.

BIO-Europe

October 24 - 26, 2022

Leipzig, Germany. Jeff Lange, Virogin Biotech EVP Business Development, will present an overview of Virogin Biotech and its OV platforms and will participate in one-to-one partnering meetings.

14th International Oncolytic Virotherapy Conference (IOVC 2022)

October 23 - 26, 2022

Nagano, Japan. Dr. William Jia, Virogin Biotech CSO, will present “New strategies for oncolytic virotherapy: turning anti-viral immunity to anti-tumor” at a session on Novel Viral Platforms on October 24.